The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Mosquito-Borne Chikungunya Virus Can Cause Long-Term Arthritis

Mosquito-Borne Chikungunya Virus Can Cause Long-Term Arthritis

September 20, 2018 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“Given our findings in the largest cohort study thus far for analysis of synovial fluid, it would indicate that most likely it would probably be safe to treat chikungunya arthritis with antirheumatic immunomodulating medications two years after infection, which is the standard of care in the French guidelines,”5 Dr. Chang says. Some physicians have prescribed these agents, but a rheumatologist who has experience with only a handful of patients with chikungunya arthritis “may feel a bit intimidated about using them because we don’t yet understand the pathophysiology. Our findings would indicate there is some justification for rheumatologists who may want to try these medications but have been worried about systemic viral dissemination,” she says.

You Might Also Like
  • Chikungunya Arthritis
  • Cytokine Response Provides Clues to Chikungunya Sequelae
  • Experimental Drug Combination Curbs Chikungunya Arthritis in Mice
Explore This Issue
September 2018
Also By This Author
  • ACR Issues sJIA Recommendations, SSc Classification Criteria

Dr. Mahalingam and colleagues say that in the absence of national guidelines, practicing rheumatologists “may … consider an early switch to DMARDs from the eighth week after the onset of infection—to be discontinued after several months of disease inactivity monitored on serial DAS28 scale measurements.” The researchers recommend that biologics be reserved for cases with evidenced refractory synovitis “as a conservative option when conventional synthetic DMARDs are not sufficient. No experimental antiviral drugs targeting viral replication (or host factors) have yet been tested in clinical trials.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

They highlight the need for multidisciplinary management of chronic CHIKV disease, with practicing rheumatologists joining with a pain specialist, a physiotherapist and even a neurologist or psychiatrist as needed. Additionally, morphological assessment (designed to evaluate the fulfillment of current criteria for rheumatoid arthritis or spondyloarthritis) and laboratory tests are generally performed to confirm the diagnosis and screen for evidence of inflammatory rheumatic disorders or other destructive mechanisms.

More research about the molecular mechanisms tied to chronic disease is needed, as well as guidance on treatment of patients who can suffer debilitating symptoms years after initial infection. “The medications we are using to treat chikungunya arthritis are empiric anti-inflammatory immunomodulating medications without truly understanding the mechanism whereby chikungunya causes arthritis,” says Dr. Chang.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

She and her colleagues are now exploring the epigenetics of patients with chikun­gunya. “We have found that patients with chikungunya arthritis have epigenetic changes that [healthy] patients do not have. If we can identify how chikungunya alters the immune response, we would then be able to provide targeted therapies as opposed to providing more empiric therapies,” she says.


Kathy Holliman, MEd, has been a medical writer and editor since 1997.

References

  1. Zaid A, Gérardin P, Taylor A, et al. Chikungunya arthritis: Implications of acute and chronic inflammation mechanisms on disease management. Arthritis Rheumatol. 2018 Apr;70(4);484–95.
  2. Chang AY, Encinales L, Porras A, et al. Frequency of chronic joint pain following chikungunya virus infection: A Colombian cohort study. Arthritis Rheumatol. 2018 Apr;70(4):578–584.
  3. Chang AY, Martins KAO, Encinales L, et al. Chikungunya arthritis mechanisms in the Americas: A cross-sectional analysis of chikungunya arthritis patients 22 months after infection demonstrating no detectable viral persistence in synovial fluid. Arthritis Rheumatol. 2018 Apr;70(4):585–593.
  4. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol. 2010 May 15;184(10):5914–5927.
  5. Simon F, Javelle E, Cabie A, et al. French guidelines for the management of chikungunya (acute and persistent presentations). Med Mal Infect. 2015 Jul;45(7):243–263.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions Tagged With: chikungunya, CHIKVIssue: September 2018

You Might Also Like:
  • Chikungunya Arthritis
  • Cytokine Response Provides Clues to Chikungunya Sequelae
  • Experimental Drug Combination Curbs Chikungunya Arthritis in Mice
  • Chikungunya Fever May Trigger Chronic Articular Symptoms

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.